Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Dec 12, 7:38PM CST
Cramer will be watching company earnings while keeping an eye on oil futures to get a sense of where the market will move.
MMM: 157.12 (-2.03), SWX: 57.19 (-1.09), HON: 95.88 (-2.01), NKE: 96.17 (-0.76), CHTR: 162.95 (-1.21), BBRY: 9.84 (-0.32), XON: 27.01 (+0.35), RMTI: 8.20 (+0.04), KMX: 58.30 (-1.21), MEMP: 13.13 (-0.96), ACAD: 32.53 (-0.10), PAYX: 46.10 (-0.77), AGU: 91.53 (-2.47), TRUE: 21.35 (-1.68), LOW: 64.87 (-0.89), TWTR: 37.10 (+0.40), REGN: 416.44 (-7.91), JOY: 46.28 (-2.80), FDX: 175.79 (-1.09), LBRDA: 49.07 (-1.58), FINL: 28.32 (+0.15), ORCL: 39.95 (-0.81), DRI: 57.38 (-0.45), BAX: 71.77 (-1.34), RHT: 57.87 (-0.55), AGIO: 119.56 (+0.36), PAY: 33.01 (-1.47), PG: 89.55 (-0.86)
Agios Pharmaceuticals (AGIO) Looks Good: Stock Up 6.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:25AM CST
Agios Pharmaceuticals (AGIO) was a big mover last session, with shares rising nearly 7% on the day.
ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), AGIO: 119.56 (+0.36), OSUR: 9.49 (-0.25)
The Nominees for Best Biotechnology Co. CEO of 2014 Are...
at The Street - Fri Dec 12, 5:05AM CST
The CEOs of Exact Sciences, Idenix Pharma, Prosensa, Agios, Bluebird Bio and InterMune vie for the coveted title of Best Biotech CEO
BLUE: 91.28 (+5.16), RNA: 18.76 (-0.21), EXAS: 27.96 (-0.24), AGIO: 119.56 (+0.36)
Agios prices offering
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 11:19AM CST
AGIO: 119.56 (+0.36)
Agios Pharmaceuticals expects USD220m from public offering
M2 - Thu Dec 11, 5:56AM CST
Biopharmaceutical company Agios Pharmaceuticals (NasdaqGS:AGIO) said on Wednesday that it has priced its public offering of 1,986,455 shares of its common stock.
AGIO: 119.56 (+0.36)
Jim Cramer's Top Stock Picks: RH COST AGIO BLUE ISIS
at The Street - Thu Dec 11, 5:00AM CST
Restoration Hardware and Costco should benefit from lower oil prices, and the recent drop in Agios' and Bluebird Bio's shares means a buying opportunity, Cramer says.
BLUE: 91.28 (+5.16), RH: 93.59 (-0.40), ISIS: 62.32 (+0.45), COST: 137.88 (-3.53), AGIO: 119.56 (+0.36)
Cramer's Mad Money - The Good Isis (12/10/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Thu Dec 11, 3:43AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday December 10. CEO Interview: Dr. Stanley Crooke, Isis Pharmaceuticals (NASDAQ: ISIS ) Isis Pharmaceuticals ( ISIS ) produces treatments that bind to...
BLUE: 91.28 (+5.16), TSLA: 207.00 (-1.88), RH: 93.59 (-0.40), FRPT: 17.14 (-0.88), BA: 120.77 (-2.60), CELG: 114.49 (-2.25), XLV: 68.78 (-1.07), RFMD: 15.50 (-0.29), NOV: 61.55 (-1.46), ISIS: 62.32 (+0.45), KITE: 54.79 (+0.39), TQNT: 25.87 (-0.51), COST: 137.88 (-3.53), AGIO: 119.56 (+0.36), VZ: 45.58 (-0.78), CSCO: 26.85 (-0.14)
Agios Pharmaceuticals Announces Pricing of $220 Million Public Offering of Common Stock
GlobeNewswire - Wed Dec 10, 7:41PM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 1,986,455 shares of common stock at a price to the public of $110.75 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $220 million. All of the shares in the offering are to be sold by Agios. Agios has also granted the underwriters a 30-day option to purchase up to an additional 297,968 shares of common stock on the same terms and conditions. Closing of the offering is expected to occur on or about December 16, 2014, subject to customary closing conditions.
JPM: 60.04 (-1.10), AGIO: 119.56 (+0.36)
Jim Cramer's 'Mad Money' Recap: The Good News-Bad News of Lower Oil Prices
at The Street - Wed Dec 10, 7:41PM CST
The negative effects of oil below $60 per barrel on certain companies could outweigh the gains seen from higher consumer spending, at least in the short term, Cramer says.
TSLA: 207.00 (-1.88), RH: 93.59 (-0.40), F: 14.99 (-0.29), EMES: 44.67 (+0.92), BOKF: 58.67 (-1.75), FRPT: 17.14 (-0.88), BPT: 67.95 (-2.57), HBHC: 29.40 (-0.82), PBR: 7.11 (-0.31), T: 32.16 (-0.55), CFR: 70.00 (-1.62), SAVE: 68.12 (-0.88), JPM: 60.04 (-1.10), COST: 137.88 (-3.53), XLF: 24.14 (-0.48), BLUE: 91.28 (+5.16), BA: 120.77 (-2.60), CELG: 114.49 (-2.25), ISIS: 62.32 (+0.45), KITE: 54.79 (+0.39), CONN: 17.44 (+0.35), JCP: 6.38 (+0.29), GM: 31.57 (-0.62), AGIO: 119.56 (+0.36), PAY: 33.01 (-1.47)
Agios Pharmaceuticals to issue up to USD175m common stock in public offering
M2 - Wed Dec 10, 6:26AM CST
Biopharmaceutical company Agios Pharmaceuticals (NasdaqGS:AGIO) said on Tuesday that it plans to launch up to USD175m of its common stock in a public offering.
AGIO: 119.56 (+0.36)
Agios Pharmaceuticals hires Kaye Foster-Cheek to board
M2 - Wed Dec 10, 6:11AM CST
Cancer company Agios Pharmaceuticals (NasdaqGS:AGIO) revealed on Tuesday the addition of Kaye Foster-Cheek as an independent director of its board of directors.
AGIO: 119.56 (+0.36)
Agios Pharmaceuticals Announces Proposed Offering of Common Stock
GlobeNewswire - Tue Dec 09, 3:22PM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to $175 million of its common stock in an underwritten public offering. Agios also intends to grant the underwriters a 30-day option to purchase from it up to an additional $26.3 million of shares. All of the shares in the offering are to be sold by Agios. The proceeds of the offering are expected to be used to fund the company's clinical and research development activities. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
JPM: 60.04 (-1.10), AGIO: 119.56 (+0.36)
Agios Pharmaceuticals Appoints Kaye Foster-Cheek to its Board of Directors
GlobeNewswire - Tue Dec 09, 3:01PM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the addition of Kaye Foster-Cheek as an independent director to the company's board of directors, effective immediately. Ms. Foster-Cheek is the former senior vice president, global human resources at Onyx Pharmaceuticals, Inc. an Amgen subsidiary. Agios' board also appointed Ms. Foster-Cheek as a member of its compensation committee and elected her to the class of directors whose term expires in 2015. The company's board now has a total of 10 members.
AGIO: 119.56 (+0.36)
Agios (AGIO) Reports Encouraging Data on Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 3:35PM CST
Agios Pharmaceuticals, Inc. (AGIO) announced new data from the ongoing phase I dose escalation study on pipeline candidate AG-221.
AGN: 208.47 (-2.67), BIIB: 344.49 (+2.16), AGIO: 119.56 (+0.36), CELG: 114.49 (-2.25)
Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency
GlobeNewswire - Mon Dec 08, 12:00PM CST
AG-348 Achieved Proof-of-Mechanism Through Substantial Effects on Two Key Biomarkers of Pyruvate Kinase Activity and Pathway Activation
AGIO: 119.56 (+0.36)
Agios Announces Celgene Decision to Extend Discovery Phase of Global Strategic Collaboration to April 2016
GlobeNewswire - Mon Dec 08, 6:30AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that Celgene Corporation has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement. The two companies have been working together since April 2010 to discover, develop and commercialize disease-altering therapies in oncology arising from Agios' cancer metabolism research platform. The extension marks the final year for the discovery phase as outlined under the terms of the collaboration, which gives Celgene an exclusive option to drug candidates generated by Agios' cancer metabolism platform during this time. The terms of the collaboration extension are consistent with previously agreed upon financial terms.
AGIO: 119.56 (+0.36), CELGZ: 3.51 (-0.03)
The 7 Most Important Drug-Stock Lessons From This Weekend's Blood Cancer Meeting
at The Street - Mon Dec 08, 6:15AM CST
Here's what I learned about biotech and drug stocks after covering the American Society of Hematology annual meeting.
BLUE: 91.28 (+5.16), SGEN: 32.25 (-1.49), MRK: 57.72 (-1.62), SNSS: 2.26 (unch), AGIO: 119.56 (+0.36), BMY: 58.75 (-0.93), XLRN: 41.77 (+0.29), NVS: 93.52 (-0.82), CELG: 114.49 (-2.25)
Cramer's Mad Money - Ulta Salon Is Looking Good (12/5/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Mon Dec 08, 4:43AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday December 5. Ulta Salon (NASDAQ: ULTA ) Is Looking Good Ulta Salon ( ULTA ) was up on Friday, and Cramer recalled a time when it seemed management was...
RH: 93.59 (-0.40), UTX: 112.15 (-1.89), CAH: 79.30 (-1.17), AMGN: 164.53 (-1.55), DIS: 91.49 (-0.26), AZO: 604.73 (+2.34), GILD: 104.13 (-0.18), SHPG: 213.70 (-0.41), COST: 137.88 (-3.53), ABBV: 65.27 (-1.76), AGIO: 119.56 (+0.36), DOV: 67.82 (-2.33), ULTA: 128.67 (-0.77), IDXX: 148.86 (-0.23), LE: 47.60 (+0.77), MBLY: 40.78 (-1.19)
3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 07, 11:39AM CST
Source: Flickr user Tax Credits Dividend paying companies are a key part of any investor's long-haul portfolio, but investors that lean toward high growth industries like biotechnology have few dividend-paying options. Despite multibillion...
BIIB: 344.49 (+2.16), ISIS: 62.32 (+0.45), OMED: 19.77 (-0.42), GILD: 104.13 (-0.18), TEVA: 55.92 (-0.92), EPZM: 18.35 (-1.45), AGIO: 119.56 (+0.36), SNY: 45.16 (-1.05), FOLD: 8.15 (+0.18), XLRN: 41.77 (+0.29), NVS: 93.52 (-0.82), CELG: 114.49 (-2.25)
Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies
GlobeNewswire - Sun Dec 07, 11:30AM CST
Durable Responses Observed with Patients on Study for up to Eight Months and Ongoing in Advanced Acute Myeloid Leukemia and Other Blood Cancers
AGIO: 119.56 (+0.36)